Skip to main content

Table 2 Basic clinical and epidemic features based on antiviral drugs usage (four groups)

From: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Feature Control (n = 45) Other antiviral drugs (n = 45) Arbidol only (n = 90) Arbidol + other antiviral drugs (n = 40)
Age [years, M (IQR)]a 51 (40, 61) 52 (45, 59) 48 (36, 56) 51 (38, 58)
 > 50 years (%) 25 (55.6) 27 (60.0) 39 (43.3) 20 (50.0)
 Male (%) 22 (48.9) 25 (55.6) 52 (57.8) 20 (50.0)
Underlying disease (%)b 7 (15.6) 9 (20.0) 13 (14.4) 14 (35.0)
Onset symptoms
 Fever (%) 27 (60.0) 37 (82.2) 77 (85.6) 35 (87.5)
 Less than 3 onset symptoms (%)c 29 (64.4) 23 (51.1) 57 (63.3) 25 (62.5)
Lab examination
 WBC (× 109/ L, M (IQR)) 5.3 (4.5, 6.2) 4.9 (4.3, 6.1) 5.4 (4.4, 6.5) 5.7 (4.1, 7.2)
Neutrophils % [M (IQR)] 65.5 (57.2, 70.3) 66.5 (61.5, 69.3) 62.8 (55.9, 71.1) 65.3 (54.4, 73.9)
Lymphocyte % [M (IQR)] 22.0 (16.9, 27.8) 24.6 (20.4, 29.1) 23.1 (17.6, 32.2) 24.2 (18.0, 32.7)
Platelet [× 109/L, M (IQR)] 167.0 (143.0, 234.0) 160.0 (130.8, 201.8) 165.0 (142.5, 209.5) 179.0 (150.5, 232.5)
CT findings
 Lung region distribution
  Unilateral (%) 1 (2.2) 1 (2.2) 1 (1.1) 0 (0.0)
  Bilateral (%) 44 (97.8) 44 (97.8) 89 (98.9) 39 (97.5)
  Absence of lesion (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.5)
 Lesions feature
  GGOsd 18 (40.0) 19 (42.2) 41 (45.5) 24 (60.0)
  Scattered patchy infiltration with interstitial alteration 18 (40.0) 21 (46.7) 24 (26.7) 8 (20.0)
  Consolidation 1 (2.2) 1 (2.2) 7 (7.8) 0 (0.0)
  More than one feature 8 (17.8) 4 (8.9) 18 (20.0) 7 (17.5)
 Other antiviral drugs
  Oseltamivir (%) 0 (0.0) 41 (91.2) 0 (0.0) 39 (97.5)
  Ribavirin (%) 0 (0.0) 1 (2.2) 0 (0.0) 1 (2.5)
  Ganciclovir (%) 0 (0.0) 1 (2.2) 0 (0.0) 0 (0.0)
  Prezcobix (%) 0 (0.0) 1 (2.2) 0 (0.0) 0 (0.0)
  Oseltamivir + Ribavirin (%) 0 (0.0) 1 (2.2) 0 (0.0) 0 (0.0)
 Other treatments except for antiviral drugs
  Antibiotics 23 (51.1) 31 (68.9) 57 (63.3) 28 (70.0)
  Chinese medicine (Lian Hua Qing Wen) 36 (80.0) 36 (80.0) 73 (81.1) 35 (87.5)
  Methylprednisolone 0 (0.0) 1 (2.2) 1 (1.1) 0 (0.0)
  Gamma immunoglobulin 1 (2.2) 0 (0.0) 2 (2.2) 0 (0.0)
  1. aM(IQR) medium (inter quartile range)
  2. bIncluding diabetes mellitus, high blood pressure, coronary heart disease, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, asthma, chronic liver disease, history of breast cancer, gout, rheumatoid arthritis and retrobulbar duodenal ulcer
  3. cIncluding dry cough, expectoration, chest tightness and shortness of breath, fatigue, muscle soreness, stuffy running nose, headache, pharyngalgia, thoracalgia, dyspnea, phlegm blood, chills and poor appetite
  4. dGGOs ground-glass opacity